Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?

5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Wendy H., Minhas, Ahmed, Baumrucker, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517765/
https://www.ncbi.nlm.nih.gov/pubmed/33542850
http://dx.doi.org/10.6004/jadpro.2020.11.1.4
_version_ 1783587289595641856
author Vogel, Wendy H.
Minhas, Ahmed
Baumrucker, Steven
author_facet Vogel, Wendy H.
Minhas, Ahmed
Baumrucker, Steven
author_sort Vogel, Wendy H.
collection PubMed
description 5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet the criteria for a routine screening test prior to 5-FU therapy. A case study of a fatality secondary to capecitabine toxicity is reviewed and literature is examined regarding general screening for DPD deficiency.
format Online
Article
Text
id pubmed-7517765
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-75177652021-02-03 Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen? Vogel, Wendy H. Minhas, Ahmed Baumrucker, Steven J Adv Pract Oncol Grand Rounds 5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet the criteria for a routine screening test prior to 5-FU therapy. A case study of a fatality secondary to capecitabine toxicity is reviewed and literature is examined regarding general screening for DPD deficiency. Harborside Press LLC 2020 2020-01-01 /pmc/articles/PMC7517765/ /pubmed/33542850 http://dx.doi.org/10.6004/jadpro.2020.11.1.4 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc-nd/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Grand Rounds
Vogel, Wendy H.
Minhas, Ahmed
Baumrucker, Steven
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
title Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
title_full Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
title_fullStr Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
title_full_unstemmed Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
title_short Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
title_sort dihydropyrimidine dehydrogenase deficiency: to screen or not to screen?
topic Grand Rounds
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517765/
https://www.ncbi.nlm.nih.gov/pubmed/33542850
http://dx.doi.org/10.6004/jadpro.2020.11.1.4
work_keys_str_mv AT vogelwendyh dihydropyrimidinedehydrogenasedeficiencytoscreenornottoscreen
AT minhasahmed dihydropyrimidinedehydrogenasedeficiencytoscreenornottoscreen
AT baumruckersteven dihydropyrimidinedehydrogenasedeficiencytoscreenornottoscreen

Ejemplares similares